Mayank Bansal, CFA
Mayank Bansal is a CFA Charterholder and heads the Equity Research team at Kapitales Research, with over 5 years of experience analysing global equity markets. He leads fundamental, data-driven research combining rigorous financial analysis with macro trends.
3 ASX Stocks in Focus: Revised AU$3.00 Takeover Bid, Director Exit and Cancer Trial Progress Lift Shares
Highlights:
Introduction
Three ASX-listed companies saw their shares trade higher after releasing fresh updates between 22 October and 11 November 2026. The news covers a takeover approach, a board change and clinical trial progress.
Stocks in Focus
Takeover Approach Returns at AU$3.00
In an announcement dated 11 November 2026, IDP Education revealed that it received a new unsolicited proposal after the market closed on 10 November. Blackstone wants to buy all of the company's shares through a recommended scheme of arrangement at AU$3.00 in cash per share. Any dividends declared after 10 November would reduce that price. The board had unanimously rejected earlier offers, saying they undervalued the business and came at an opportunistic time. It is now weighing the revised proposal for shareholders as a whole. No decision has been made, and shareholders need not act.
Director Steps Down, Holdings Disclosed
COG Financial Services lodged a final director's interest notice showing that Cameron McCullagh ceased to be a director on 9 November 2026. He holds no shares in his own name. His related interests total 6,469,192 ordinary shares, spread across three holders: 2,929,814 through a related company, 1,708,140 through his spouse's investment company, and 1,831,238 through a family super fund. The notice reports no interests in contracts.
Cancer Trials Move Forward
On 22 October 2026, Racura Oncology released its September quarter report. The company treated its first patient with its RC220 drug alongside osimertinib in a lung cancer trial, and no dose-limiting toxicities were reported. A separate heart-protection trial expanded to South Korea, and ethics approvals opened more Australian trial sites. In October, the safety committee cleared the lung cancer trial to move to a higher dose. Racura ended the quarter with AU$30.7 million in cash after a net operating outflow of AU$3.54 million. Management says this funds committed activities into mid-2028.
Outro
These updates show how takeover interest, boardroom changes and clinical progress can each move a share price. Investors should read the full announcements and seek professional advice before making any decisions.
Note: All data presented is based on information available at the time of writing.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au